Pharyngocutaneous fistula as an alternative access route for inserting a percutaneous endoscopic gastrostomy tube in head and neck cancer patients

Authors
Louise Deluiz Verdolin Di Palma, Gustavo Francisco de Souza e Mello, Cindy Lis Granados, Ricardo Dardengo Glória, Caroline Sauter Dalbem, Rolantre Lopes da Cruz, Ana Carolina Maron Ayres, Renata Sofia Camara Lisboa, Alexandre Dias Pelosi, Maria Aparecida Ferreira, Gilberto Reynaldo Mansur, Simone Guaraldi da Silva, Theresa Christina Damian Ribeiro, Fernando Luiz Dias

Institution
Department of Digestive Endoscopy, Cancer Hospital I, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

accepted after revision: 2.3.2017

Bibliography

Corresponding author
Gustavo Francisco de Souza e Mello, MD, PhD, Department of Digestive Endoscopy, Cancer Hospital I, Brazilian National Cancer Institute, Praça Cruz Vermelha 23, Rio de Janeiro – RJ, CEP 20230-130
gmello@inca.gov.br
gfsmello@gmail.com

ABSTRACT

Background and study aims Performing a percutaneous endoscopic gastrostomy (PEG) in head and neck cancer (HNC) patients can be challenging because of the presence of trismus, pharyngeal obstruction by tumor, and pharyngo-esophageal strictures or fistula. Pharyngocutaneous fistula (PCF) is a major postoperative concern in patients submitted to total laryngectomy (TL). In the medical literature to date, the cervical fistula has been used as an access to PEG in only four reports. The aim of this study was to evaluate the safety of cervical fistula for insertion of a PEG tube.

Patients and methods Retrospective study at a single tertiary referral center, regarding the technical feasibility, safety and outcomes of a PEG tube introduced by a cervical fistula in HNC patients with obstructive lesions of the oropharynx.

Results The procedure was technically successful in all 21 patients. A PEG tube was used for a minimum of 1 month and a maximum of 120 months. Twelve patients died while using the PEG tube, 8 had it taken out because it was no longer needed, and only 1 had the tube still in use. Adverse events occurred in 8 patients: granuloma (19 %), dermatitis (9.5 %), accidental late removal of the tube (9.5 %), periprocedural gastric wall hematoma (9.5 %), peristomal wound infection (4.7 %), buried bumper syndrome (4.7 %), and traumatic gastric ulcer (4.7 %).

Conclusion A postoperative cervical fistula can successfully work as a reliable and safe access for a PEG tube procedure in HNC patients, avoiding unnecessary surgery and reducing costs.

Introduction
Nutritional support is a critical point in the care of patients with advanced cancer. In general, patients with malignancies suffer malnutrition from tumor burden and/or anorexia. Head and neck cancer (HNC) patients have additional problems because swallowing disorders are caused by pharyngeal strictures, fistula, and damage to the pharyngeal musculature resulting from the tumor, radiation therapy, or surgical procedure. Nevertheless, the gastrointestinal tract in these individuals usually is intact, making them fit for enteral nutrition. In these patients, nourishment can be administered through nasoenteric tubes or gastrostomy tubes placed by endoscopy, radioscopy or laparotomy [1, 2].

In 1980, Gauderer et al. first described insertion of a percutaneous gastrostomy tube under local anesthesia using endoscopy, in a child [3]. A percutaneous endoscopic gastrostomy (PEG) tube has rapidly become the most widely used method for long-term feeding, because it is safer and more cost-effec-
tive than surgically placed gastrostomies, with a low rates of procedure-related mortality and complications [4, 5].

Considerations for performing a PEG in HNC patients include dealing with the presence of trismus, pharyngeal obstruction caused by tumor mass, pharyngoesophageal strictures or fistula, difficult airway, and the timing of PEG with respect to surgery, radiation, and chemotherapy for the oropharyngeal malignancy [1, 6].

Because of these difficulties, endoscopists have to be resourceful and find different ways to bypass the technical and anatomic limitations. Regarding the strictures, maneuvers that allow PEG tube placement in these patients include the selection of a small-caliber endoscope and pharyngoesophageal dilatation [1]. In different reports, upper aerodigestive tract obstruction accounted for 20% to 75% of all PEG tube placement failures in HNC patients [1, 7]. In some clinical scenarios with surgical HNC patients, if an endoscopist is unable to bypass a local stricture or a trismus, a postoperative cervical fistula (frequent treatment sequelae in these patients) or an esophagostomy can be used to introduce the endoscope.

Pharyngocutaneous fistula (PCF) is a major post-treatment concern in patients who undergo total laryngectomy (TL). The reported incidence of PCF following TL for laryngeal cancer ranges from 2.6% to 65.5% [8]. The fistula may be secondary to impaired wound healing, persistent distal obstruction to saliva flow, technical difficulties during pharyngoplasty or local tissue ischemic necrosis, which general occurs within the first few postoperative days [9, 10].

The fistula was used for access to insert a PEG tube was reported by Hunter et al. in 1989 [1], when they described 1 case among 50 successful PEGs in HNC patients. Since then, only a few reports have been described in the medical literature. Our aim was to report our experience with use of a postoperative cervical fistula as an alternative access route for PEG tube placement in HNC patients with obstructive lesions of the oropharyngeal region.

Patients and methods

Study design

Retrospective review of prospectively collected clinical data, presented as a case series of consecutive HNC patients undergoing PEG done through a post-treatment cervical fistula or stoma, conducted at the Department of Digestive Endoscopy of the Brazilian National Cancer Institute (INCA), a federal government tertiary referral center, at Rio de Janeiro, Brazil.

Clinical and demographic data on the patients, adverse events (AEs), and patient outcomes were recorded in an Excel spreadsheet (Microsoft Corp., Redmond, Washington, United States) during long-term follow-up.

This study protocol was approved by the INCA Institutional Review Board (CEP/INCA Number 1706). Informed consent was obtained from all patients.

Study population

From January 2002 to December 2014, 1305 PEG procedures were done in HNC patients at our institution. Of them, 21 PEG procedures were performed in the same number of adult HNC patients with obstructive lesions of the oral cavity or hypopharynx by inserting the endoscope and PEG tube directly through a cervical fistula or stoma.

Operative technique

Prophylactic intravenous cephazolin (2 g) was given to all patients 30 minutes before the procedure. Under pulse oximetry continuous monitoring and conscious sedation with intravenous midazolam and meperidine, a standard-diameter or pediatric gastroesophagoscope was inserted through the cervical (pharyngogastrocutaneous) fistula, and the upper gastrointestinal tract was thoroughly examined via endoscopy. PEG was performed using the “pull” method (Gauderer-Ponsky technique) using commercially available kits (PEG 24-Pull-S, Cook Medical, Winston-Salem, North Carolina, United States; MIC PEG 24 Fr, Ballard Medical Products, Draper, Utah, United States; and EndoVive PEG 24 Fr, Boston Scientific Corporation, Natick, Massachusetts, United States).

Follow-up

Following the institutional post-PEG protocol, patients returned for regular visits at scheduled intervals (on post-procedure days 2 and 7, and then monthly) during the period of PEG use, until the tube was removed or the patient died.

Definition of adverse events

AEs were considered minor when they required simple or ambulatory care (late dislodged tube, peristomal leak, wound infection, granuloma formation, minor wound bleeding or small hematoma). Major AEs included peritonitis, buried bumper syndrome (BBS), sepsis, aspiration pneumonia, hemorrhage, gastric perforation, gastrocutaneous fistula and any AEs requiring a repeat procedure, surgical or endoscopic treatment, or blood transfusion [11].

Results

Results are summarized in Table 1.

A standard-diameter or pediatric gastroesophagoscope was passed through a cervical fistula or stoma and a pull-technique PEG was performed in a total of 21 HNC patients (3 female and 18 male). The age of patients varied from 34 to 84 years (mean 59 years).

Eighteen (85.7%) patients had laryngeal cancer, 2 (9.5%) had oropharyngeal cancer, and 1 (4.7%) had hypopharyngeal cancer. All of them had undergone a radical surgical procedure (2 had a combined mandibulectomy and neck dissection operation [COMMANDO surgery], and 19 had a total laryngectomy). Four (19%) of those patients had complementary treatment with chemotherapy and radiation therapy, and 9 (42.8%) had radiation therapy alone.
PEG was performed as an outpatient procedure (ambulatory setting, without hospitalization) in 8 (38.1%) of 21 patients. Preprocedure endoscopic dilation of a fibrotic and narrowed esophageal opening (with a Savary bougie or a hydrostatic balloon) was necessary for 3 (14.3%) patients, to allow advancement of the endoscope.

Eight patients (38.1%) presented with PEG complications, with more than one event per patient in 4 cases (1 patient with 3 different complications and 3 patients with 2 complications each), for a total of 13 AEs: granuloma formation (4 cases; 19%), dermatitis (2 cases; 9.5%), accidental late removal of the tube (2 cases; 9.5%), peri-procedural gastric wall hematoma (2 cases; 9.5%), peristomal wound infection (1 case; 4.8%), BBS (1 case; 4.8%), traumatic gastric ulcer (1 case; 4.8%). The rate of major AEs was 4.8% (1 patient) and minor AEs was 38.1% (8 patients). There were no fatalities related to the PEG procedure.

In the follow-up, a PEG tube was used for a minimum of 1 month and a maximum of 120 months (mean of 17.9 months). Of all the patients, 12 (57.1%) died while using the PEG tube, 8 (38.1%) had the PEG tube taken out because it was no longer needed, and only 1 (4.8%) had the tube still in use.

**Discussion**

Numerous techniques are currently available for inserting a PEG tube in difficult HNC patients [12, 13]. The route for introducing the endoscope into the stomach is one of the crucial points of the procedure. In most cases, peroral gastroscopy and pull-technique PEG placement are easy and safe. However, in the presence of severe trismus, tumor obstruction, or post-treatment anatomic changes, the procedure may become impractical. Introducer PEG technique by transnasal approach with ultrathin endoscopes, rigid laryngoscopic guidance, radiologic percutaneous gastrostomy (RPG), transmaxillary approach, intraoperative procedures (surgically opened pharynx region), and open surgical gastrostomy must be considered to insert a G-tube successfully in these difficult cases [12, 13]. To avoid a surgical procedure, an existing cervical fistula or ostomy may be used to provide access to the PEG tube, if the procedure cannot be performed transorally [1, 14, 15].

For the 21 HNC patients included in this case series, there were 2 main indications for the introduction of the endoscope directly through a cervical fistula or stoma. The first (and more frequent indication) was the finding of a tumoral or cicatricial obstruction of the oral cavity or hypopharynx region that precluded tube progression. The second reason was the presence of an extensive anterior cervical wall defect that resulted in complete exteriorization of the endoscope tube after the transposition of the hypopharynx (▶Fig. 1). In the latter situation, even it was possible to advance the tube, introduction of the endoscope through the mouth would result in an unnecessary maneuver and pose an elevated risk of contamination of the PEG tube, which could result in a higher rate of peristomal infection. In the majority of cases, the two situations were present simultaneously.

Until today, only 4 reports in the medical literature have described use of cervical access (by a preexisting fistula or stoma) to perform a PEG in HNC patients [1, 14–16]. Hunter et al. reported the first description of PEG tube insertion through a cervical fistula in 1989 [1]. At that time, they presented the experience of performing PEG in 50 patients

---

**Table 1** Patient characteristics.

<table>
<thead>
<tr>
<th></th>
<th>HNC patients, no. (%)</th>
<th>Age, median (IQR), y</th>
<th>Gender, no. (%)</th>
<th>Tumor location, no. (%)</th>
<th>Tumor treatment, no. (%)</th>
<th>PEG procedure setting, no. (%)</th>
<th>PEG procedures with complication, no. (%)</th>
<th>PEG adverse event, no. (%)</th>
<th>Follow-up, median (IQR), m</th>
<th>Outcome, no. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HNC patients, no. (%)</td>
<td>21 (100)</td>
<td>59 (34 – 84)</td>
<td>Male</td>
<td>18 (85.7)</td>
<td>Larynx</td>
<td>Inpatient</td>
<td>13 (61.9)</td>
<td>8 (38.1)</td>
<td>4 (19.0)</td>
<td>17.9 (1 – 120)</td>
</tr>
<tr>
<td>Age, median (IQR), y</td>
<td></td>
<td></td>
<td>Female</td>
<td>3 (14.3)</td>
<td>Oropharynx</td>
<td>Outpatient (ambulatory)</td>
<td>8 (38.1)</td>
<td>8 (38.1)</td>
<td>2 (9.5)</td>
<td></td>
</tr>
<tr>
<td>Gender, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hypopharynx</td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>Tumor location, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td>12 (57.1)</td>
</tr>
<tr>
<td>Tumor treatment, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td>8 (38.1)</td>
</tr>
<tr>
<td>PEG procedure setting, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>PEG procedures with complication, no. (%)</td>
<td>8 (38.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8 (38.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEG adverse event, no. (%)</td>
<td>4 (19.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>Granulation tissue</td>
<td>4 (19.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>Dermatitis</td>
<td>2 (9.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>PEG tube placement</td>
<td>2 (9.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>Gastric hematoma</td>
<td>2 (9.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>Stomal infection</td>
<td>1 (4.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>Traumatic gastric ulcer</td>
<td>1 (4.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>BBS</td>
<td>1 (4.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 (9.5)</td>
<td>2 (9.5)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
<tr>
<td>Follow-up, median (IQR), m</td>
<td>17.9 (1 – 120)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17.9 (1 – 120)</td>
<td>17.9 (1 – 120)</td>
<td>17.9 (1 – 120)</td>
<td></td>
</tr>
<tr>
<td>Outcome, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17.9 (1 – 120)</td>
<td>17.9 (1 – 120)</td>
<td>17.9 (1 – 120)</td>
<td></td>
</tr>
<tr>
<td>Death (disease progression)</td>
<td>12 (57.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12 (57.1)</td>
<td>12 (57.1)</td>
<td>12 (57.1)</td>
<td></td>
</tr>
<tr>
<td>PEG removed</td>
<td>8 (38.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8 (38.1)</td>
<td>8 (38.1)</td>
<td>8 (38.1)</td>
<td></td>
</tr>
<tr>
<td>PEG in use</td>
<td>1 (4.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 (4.8)</td>
<td>1 (4.8)</td>
<td>1 (4.8)</td>
<td></td>
</tr>
</tbody>
</table>

HNC, head and neck cancer; no, number; %, percent; IQR, interquartile range; y, years; RTx, radiotherapy; CHt, chemotherapy; PEG, percutaneous endoscopic gastrostomy; BBS, buried bumper syndrome; m, months. 1 8 patients with a total of 13 adverse events.
with advanced oropharyngeal cancer, using a pull-through PEG technique. In one of the patients they used an esophagocutaneous fistula as an access via to inserting the PEG tube.

In 2001, Lujber et al. described a 59-year-old patient with a squamous cell carcinoma of the left piriform sinus who had radiation and surgical treatment [14]. Two weeks after the operation, formation of fistula began in the neck. Since the oral route could not be used because of extensive irradiation-induced fibrosis and the postoperative narrowing lumen of the remaining hypopharynx, the fistula seemed the best way to access the stomach. Unlike our patients, who underwent PEG under conscious sedation, the procedure in Lujber et al.’s study was done under general anesthesia. Insertion of an 18 Fr PEG tube insertion through the orifice of the fistulae was successful. No major or minor AEs occurred during or after the procedure. The PEG tube was removed 4 months later. The patient had no tumor recurrence or other problems during the 24-month follow-up period.

In 2006, Lujber described 3 other cases of PEG tube insertion through a cervical fistula [15]. In all cases, the pull-type PEG technique was used. Only 1 patient had the procedure done under general anesthesia, the other 2 had local anesthesia. No immediate or long-term AEs were noted.

In a report of PEG as an outpatient procedure in HNC patients, Mello et al. used cervical fistula and pharyngoesophageal fistucomies as the access route for introducing the endoscope and the PEG tube in 6 (4.6%) of a total of 136 patients [16].

In all mentioned cases above, a pharyngoesophageal fistula was used to access the stomach lumen, and a pull-technique PEG was successfully performed. As seen, this procedure can be done using general anesthesia or intravenous conscious sedation.

All of our procedures were safely done with pull-type PEG kits (Gauderer-Ponsky method), at the endoscopy room and under conscious intravenous sedation (avoiding unnecessary general anesthesia and mechanical ventilation). In almost 40% of cases, PEG was performed as an outpatient procedure, in the ambulatory setting. At our institution, both introducer-type PEG technique (Russell method) and RPG were only regularly available after 2012.

Lujber et al. and Lujber had no AEs in any of their 4 procedures [14, 15]. Hunter et al. had AEs events classified as minor without further specifications [1]. In our report, only one major AE (a buried bumper syndrome) was seen, all other AEs were classified as minor. No patient died from the PEG procedure. Some authors reported a total AE rate of 37% to 40% in HNC patients submitted to PEG [17 – 20]. A systematic review of PEG in HNC patients reported minor AEs in 171 (13.3%) of 1281 procedures and major AEs in 60 (4.6%) [11]. Mortality occurred in 10 (0.8%) patients. Compared to PEG literature in HNC patients, our AEs occurred at the expected frequency, regardless of the relationship to or influence of introduction of the endoscope and/or PEG tube through the cervical fistula.
Conclusion

When dealing with HNC patients, the PEG procedure can be a challenge due to obstructive lesions or trismus. This report registers that a pharyngoesophagocutaneous fistula, a frequent post-treatment AE in these patients, can successfully be used as a reliable and safe access route to PEG tube introduction, avoiding unnecessary surgery and reducing costs.

Competing interests

None

References